Loxo Oncology Stock Price, News & Analysis (NASDAQ:LOXO)

$85.85 -4.14 (-4.60 %)
(As of 01/17/2018 03:04 PM ET)
Previous Close$89.99
Today's Range$85.84 - $90.79
52-Week Range$36.75 - $95.92
Volume305,800 shs
Average Volume304,940 shs
Market Capitalization$2.57 billion
P/E Ratio-14.78
Dividend YieldN/A
Beta2.54

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:LOXO
CUSIPN/A
Phone+1-203-6533880

Debt

Debt-to-Equity RatioN/A
Current Ratio21.56%
Quick Ratio21.56%

Price-To-Earnings

Trailing P/E Ratio-14.776247848537
Forward P/E Ratio-14.53
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.09 per share
Price / Book16.87

Profitability

Trailing EPS($5.81)
Net Income$-72,390,000.00
Net MarginsN/A
Return on Equity-37.71%
Return on Assets-36.12%

Miscellaneous

Employees29
Outstanding Shares29,940,000

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology, Inc. (NASDAQ:LOXO) issued its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.38) by $0.26. View Loxo Oncology's Earnings History.

When will Loxo Oncology make its next earnings announcement?

Loxo Oncology is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Loxo Oncology.

Where is Loxo Oncology's stock going? Where will Loxo Oncology's stock price be in 2018?

9 equities research analysts have issued 12-month target prices for Loxo Oncology's stock. Their forecasts range from $50.00 to $108.00. On average, they expect Loxo Oncology's stock price to reach $92.00 in the next year. View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:

  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (1/9/2018)
  • 2. BTIG Research analysts commented, "Today LOXO announced the acquisition of REDX08608 (LOXO-305) from Redx Pharma (REDX, Not Rated), a reversible BTK inhibitor that is effective against both wild-type and mutant C481S BTK. We view the acquisition of REDX08608 positively, as the ~$40m upfront acquisition cost is relatively devoid of downstream payments (milestones etc.), and despite the BTK space being competitive with next generation programs to ibrutinib, we think there will be ample room for multiple BTK inhibitors and we also favor the selectivity of LOXO-305. Management has guided for the submission of an IND during 2018. We reiterate our Buy rating and $75 PT." (8/3/2017)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:

  • Joshua H. Bilenker M.D., President, Chief Executive Officer, Director (Age 45)
  • Jennifer Burstein CPA, Vice President - Finance (Age 45)
  • Jacob S. Van Naarden, Chief Business Officer (Age 32)
  • Keith T. Flaherty M.D., Director (Age 46)
  • Lori A. Kunkel M.D., Director (Age 59)
  • Steven A. Elms, Independent Director (Age 53)
  • Alan Fuhrman, Independent Director (Age 60)
  • Steven D. Harr M.D., Independent Director (Age 46)

Who owns Loxo Oncology stock?

Loxo Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include AISLING CAPITAL III LP (12.30%) and ORBIMED ADVISORS LLC (4.87%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

How do I buy Loxo Oncology stock?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of Loxo Oncology stock can currently be purchased for approximately $85.85.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $2.57 billion. The biopharmaceutical company earns $-72,390,000.00 in net income (profit) each year or ($5.81) on an earnings per share basis. Loxo Oncology employs 29 workers across the globe.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 Tresser Blvd Fl 9, STAMFORD, CT 06901-3238, United States. The biopharmaceutical company can be reached via phone at +1-203-6533880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (LOXO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Loxo Oncology (NASDAQ:LOXO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.113.112.883.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $92.00$92.00$75.36$74.60
Price Target Upside: 24.39% upside24.39% upside14.51% downside5.16% upside

Loxo Oncology (NASDAQ:LOXO) Consensus Price Target History

Price Target History for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017William BlairInitiated CoverageOutperformHighView Rating Details
11/16/2017CitigroupLower Price TargetBuy$112.00 -> $108.00N/AView Rating Details
11/14/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$77.18 -> $95.00N/AView Rating Details
11/14/2017Ifs SecuritiesUpgradeOutperform -> Strong-BuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$95.00 -> $103.00N/AView Rating Details
9/29/2017BTIG ResearchReiterated RatingBuy$75.00 -> $102.00LowView Rating Details
9/28/2017CowenReiterated RatingBuyLowView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$71.00 -> $94.00HighView Rating Details
2/8/2017Jefferies GroupInitiated CoverageBuy$50.00N/AView Rating Details
4/19/2016OppenheimerReiterated RatingOutperform$30.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Loxo Oncology (NASDAQ:LOXO) Earnings History and Estimates Chart

Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ LOXO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($1.14)N/AView Earnings Details
11/2/2017Q3 2017($1.38)($1.12)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.99)($1.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Loxo Oncology (NASDAQ:LOXO) Earnings Estimates

2018 EPS Consensus Estimate: ($4.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.17)($1.17)($1.17)
Q2 20181($1.20)($1.20)($1.20)
Q3 20181($1.18)($1.18)($1.18)
Q4 20181($1.12)($1.12)($1.12)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Loxo Oncology (NASDAQ LOXO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.80%
Institutional Ownership Percentage: 99.98%
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ LOXO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2017Timothy M. MaylebenDirectorSell10,000$80.49$804,900.00View SEC Filing  
12/19/2017Aisling Capital Iii LpMajor ShareholderSell250,000$80.50$20,125,000.00View SEC Filing  
12/15/2017Joshua H BilenkerCEOSell15,000$81.12$1,216,800.00190,207View SEC Filing  
12/15/2017Naarden Jacob VanInsiderSell3,082$81.19$250,227.581,541View SEC Filing  
12/14/2017Jennifer BursteinVPSell1,700$83.27$141,559.001,700View SEC Filing  
12/8/2017David P BonitaDirectorSell250,000$82.50$20,625,000.00View SEC Filing  
11/28/2017Joshua H BilenkerCEOSell15,000$74.45$1,116,750.00182,707View SEC Filing  
11/28/2017Naarden Jacob VanInsiderSell3,082$74.50$229,609.001,541View SEC Filing  
11/27/2017Jennifer BursteinVPSell1,700$74.82$127,194.001,700View SEC Filing  
11/22/2017Aisling Capital Iii LpMajor ShareholderSell500,000$75.00$37,500,000.00View SEC Filing  
11/22/2017Orbimed Advisors LlcDirectorSell267,000$75.00$20,025,000.0013,000View SEC Filing  
11/20/2017Keith T FlahertyDirectorSell7,250$75.99$550,927.5012,493View SEC Filing  
11/16/2017Orbimed Advisors LlcDirectorSell270,000$74.26$20,050,200.00View SEC Filing  
11/2/2017Lori Anne KunkelDirectorSell5,000$84.91$424,550.0015,040View SEC Filing  
10/31/2017Joshua H BilenkerCEOSell7,500$86.49$648,675.00196,207View SEC Filing  
10/31/2017Naarden Jacob VanInsiderSell1,541$86.52$133,327.321,541View SEC Filing  
10/30/2017Jennifer BursteinVPSell1,700$87.19$148,223.001,700View SEC Filing  
10/16/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00144,118View SEC Filing  
9/19/2017Joshua H BilenkerCEOSell15,000$89.02$1,335,300.00196,207View SEC Filing  
9/19/2017Naarden Jacob VanInsiderSell3,082$89.00$274,298.001,541View SEC Filing  
9/18/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00149,118View SEC Filing  
9/18/2017Jennifer BursteinVPSell1,700$89.10$151,470.001,700View SEC Filing  
9/18/2017Joshua H BilenkerCEOSell7,500$89.25$669,375.00196,207View SEC Filing  
9/18/2017Naarden Jacob VanInsiderSell1,541$89.20$137,457.201,541View SEC Filing  
9/13/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00154,118View SEC Filing  
8/22/2017Lori Anne KunkelDirectorSell10,000$75.17$751,700.0016,840View SEC Filing  
8/21/2017Keith T FlahertyDirectorSell7,250$72.26$523,885.0020,432View SEC Filing  
8/15/2017Joshua H BilenkerCEOSell15,000$73.56$1,103,400.00196,207View SEC Filing  
8/15/2017Naarden Jacob VanInsiderSell3,082$73.57$226,742.741,541View SEC Filing  
8/14/2017Jennifer BursteinVPSell1,700$73.73$125,341.001,700View SEC Filing  
8/14/2017Joshua H BilenkerCEOSell7,500$73.73$552,975.00196,207View SEC Filing  
8/14/2017Naarden Jacob VanInsiderSell1,541$73.73$113,617.931,541View SEC Filing  
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.5027,141View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.5038,732View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.0045,982View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.0060,482View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50159,118View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Loxo Oncology (NASDAQ LOXO) News Headlines

Source:
DateHeadline
Loxo Oncology, Inc. (LOXO) Receives Consensus Rating of "Buy" from BrokeragesLoxo Oncology, Inc. (LOXO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 9 at 6:02 PM
Analyst Recommendations for Ignyta and Its Peers in January 2018Analyst Recommendations for Ignyta and Its Peers in January 2018
finance.yahoo.com - January 9 at 5:24 PM
A Close Look at Ignyta’s Licensing AgreementA Close Look at Ignyta’s Licensing Agreement
finance.yahoo.com - January 9 at 5:24 PM
Loxo Oncology (LOXO) Rating Increased to Hold at Zacks Investment ResearchLoxo Oncology (LOXO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 6:08 AM
Form 4 Loxo Oncology, Inc. For: Jan 04 Filed by: Bilenker Joshua H.Form 4 Loxo Oncology, Inc. For: Jan 04 Filed by: Bilenker Joshua H.
www.streetinsider.com - January 6 at 9:32 AM
Zacks: Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Post Earnings of -$1.27 Per ShareZacks: Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Post Earnings of -$1.27 Per Share
www.americanbankingnews.com - January 3 at 9:44 PM
Loxo Oncology (LOXO) Rating Lowered to Sell at Zacks Investment ResearchLoxo Oncology (LOXO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 30 at 8:56 PM
Traders Purchase High Volume of Call Options on Loxo Oncology (LOXO)Traders Purchase High Volume of Call Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - December 28 at 4:05 AM
Loxo Oncology (LOXO) Raised to Hold at BidaskClubLoxo Oncology (LOXO) Raised to Hold at BidaskClub
www.americanbankingnews.com - December 23 at 1:28 PM
Insider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 10,000 Shares of StockInsider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - December 22 at 5:54 PM
Loxo Oncology, Inc. (LOXO) Major Shareholder Aisling Capital Iii Lp Sells 250,000 SharesLoxo Oncology, Inc. (LOXO) Major Shareholder Aisling Capital Iii Lp Sells 250,000 Shares
www.americanbankingnews.com - December 20 at 5:40 PM
Redx Pharma Swings To Profit Amid Administration Dominated YearRedx Pharma Swings To Profit Amid Administration Dominated Year
www.morningstar.co.uk - December 20 at 9:33 AM
Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion CancersLoxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
finance.yahoo.com - December 20 at 9:33 AM
Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion CancersBayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers
finance.yahoo.com - December 20 at 9:33 AM
Jennifer Burstein Sells 1,700 Shares of Loxo Oncology, Inc. (LOXO) StockJennifer Burstein Sells 1,700 Shares of Loxo Oncology, Inc. (LOXO) Stock
www.americanbankingnews.com - December 18 at 9:26 PM
Insider Selling: Loxo Oncology, Inc. (LOXO) Insider Sells 3,082 Shares of StockInsider Selling: Loxo Oncology, Inc. (LOXO) Insider Sells 3,082 Shares of Stock
www.americanbankingnews.com - December 18 at 9:06 PM
Joshua H. Bilenker Sells 15,000 Shares of Loxo Oncology, Inc. (LOXO) StockJoshua H. Bilenker Sells 15,000 Shares of Loxo Oncology, Inc. (LOXO) Stock
www.americanbankingnews.com - December 18 at 8:36 PM
Loxo Oncology, Inc. (LOXO) Receives Consensus Recommendation of "Buy" from AnalystsLoxo Oncology, Inc. (LOXO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 3:52 PM
Loxo Oncology (LOXO) Upgraded to Sell at BidaskClubLoxo Oncology (LOXO) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - December 12 at 10:06 PM
Insider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 250,000 Shares of StockInsider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 250,000 Shares of Stock
www.americanbankingnews.com - December 12 at 2:38 PM
Loxo Oncology (LOXO) Reports Updated Larotrectinib Pediatric Phase 1 SCOUT Clinical Trial DataLoxo Oncology (LOXO) Reports Updated Larotrectinib Pediatric Phase 1 SCOUT Clinical Trial Data
www.streetinsider.com - December 5 at 10:12 AM
BRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion CancersBRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion Cancers
www.reuters.com - December 4 at 9:28 AM
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion CancersLoxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
finance.yahoo.com - December 4 at 9:28 AM
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancersUpdated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers
finance.yahoo.com - December 4 at 9:28 AM
Loxo Oncology Is A Buy Ahead Of Data Update - Seeking AlphaLoxo Oncology Is A Buy Ahead Of Data Update - Seeking Alpha
seekingalpha.com - December 3 at 5:19 PM
Loxo Oncology, Inc. Fundamental Analysis : November 30, 2017Loxo Oncology, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - November 30 at 5:15 PM
Loxo Oncology, Inc. (LOXO) Expected to Earn FY2017 Earnings of ($5.82) Per ShareLoxo Oncology, Inc. (LOXO) Expected to Earn FY2017 Earnings of ($5.82) Per Share
www.americanbankingnews.com - November 30 at 6:56 AM
Loxo Oncology, Inc. (LOXO) CEO Joshua H. Bilenker Sells 15,000 SharesLoxo Oncology, Inc. (LOXO) CEO Joshua H. Bilenker Sells 15,000 Shares
www.americanbankingnews.com - November 29 at 7:54 PM
William Blair Initiates Coverage on Loxo Oncology (LOXO)William Blair Initiates Coverage on Loxo Oncology (LOXO)
www.americanbankingnews.com - November 28 at 9:50 AM
Loxo Oncology, Inc. (LOXO) Major Shareholder Aisling Capital Iii Lp Sells 500,000 SharesLoxo Oncology, Inc. (LOXO) Major Shareholder Aisling Capital Iii Lp Sells 500,000 Shares
www.americanbankingnews.com - November 27 at 10:28 PM
Loxo Oncology, Inc. (LOXO) Director Sells $20,025,000.00 in StockLoxo Oncology, Inc. (LOXO) Director Sells $20,025,000.00 in Stock
www.americanbankingnews.com - November 27 at 4:38 PM
Keith T. Flaherty Sells 7,250 Shares of Loxo Oncology, Inc. (LOXO) StockKeith T. Flaherty Sells 7,250 Shares of Loxo Oncology, Inc. (LOXO) Stock
www.americanbankingnews.com - November 22 at 7:57 PM
Insider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 270,000 Shares of StockInsider Selling: Loxo Oncology, Inc. (LOXO) Director Sells 270,000 Shares of Stock
www.americanbankingnews.com - November 20 at 10:28 PM
Loxo Oncology, Inc. (LOXO) Given Consensus Rating of "Buy" by BrokeragesLoxo Oncology, Inc. (LOXO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 20 at 4:04 PM
Is Loxo Oncologys Deal With Bayer Bad News? - NasdaqIs Loxo Oncology's Deal With Bayer Bad News? - Nasdaq
www.nasdaq.com - November 19 at 7:18 PM
Investors Purchase Large Volume of Call Options on Loxo Oncology (LOXO)Investors Purchase Large Volume of Call Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - November 18 at 2:02 AM
Traders Buy Large Volume of Put Options on Loxo Oncology (LOXO)Traders Buy Large Volume of Put Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - November 17 at 2:54 AM
Citigroup Inc. Lowers Loxo Oncology, Inc. (LOXO) Price Target to $108.00Citigroup Inc. Lowers Loxo Oncology, Inc. (LOXO) Price Target to $108.00
www.americanbankingnews.com - November 16 at 6:50 PM
Loxo Oncology Enters Oversold Territory (LOXO)Loxo Oncology Enters Oversold Territory (LOXO)
www.nasdaq.com - November 15 at 5:35 AM
Loxo Oncology (LOXO) Announces Pact with Bayer for Larotrectinib and LOXO-195Loxo Oncology (LOXO) Announces Pact with Bayer for Larotrectinib and LOXO-195
www.streetinsider.com - November 15 at 5:35 AM
BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugsBRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs
www.reuters.com - November 15 at 5:35 AM
Loxo Loses Out Despite Signing Big Cancer DealLoxo Loses Out Despite Signing Big Cancer Deal
247wallst.com - November 15 at 5:35 AM
Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 BillionLoxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion
finance.yahoo.com - November 15 at 5:35 AM
Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln dealLoxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal
finance.yahoo.com - November 15 at 5:35 AM
What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?
finance.yahoo.com - November 15 at 5:35 AM
Loxos Good Deed Goes PunishedLoxo's Good Deed Goes Punished
finance.yahoo.com - November 15 at 5:35 AM
Loxo Oncology, Inc. (LOXO) Rating Increased to Strong-Buy at Ifs SecuritiesLoxo Oncology, Inc. (LOXO) Rating Increased to Strong-Buy at Ifs Securities
www.americanbankingnews.com - November 14 at 6:36 PM
Loxo Oncology, Inc. (LOXO) Upgraded to Outperform at JMP SecuritiesLoxo Oncology, Inc. (LOXO) Upgraded to Outperform at JMP Securities
www.americanbankingnews.com - November 14 at 4:00 PM
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual MeetingArray BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting
www.bizjournals.com - November 13 at 5:12 PM
-$1.29 EPS Expected for Loxo Oncology, Inc. (LOXO) This Quarter-$1.29 EPS Expected for Loxo Oncology, Inc. (LOXO) This Quarter
www.americanbankingnews.com - November 11 at 3:26 PM

SEC Filings

Loxo Oncology (NASDAQ:LOXO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Loxo Oncology (NASDAQ:LOXO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Loxo Oncology (NASDAQ LOXO) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.